Page last updated: 2020 08 11

Supporting Transplantation during the COVID-19 pandemic

As the world leader in Transplant Diagnostics, One Lambda is partnering with transplant professionals around the world to facilitate testing in the face of new challenges and to launch innovative research that may shed light on the immune response in COVID-19 patients.


Supporting the Fight Against COVID-19 with New Diagnostic Solutions

LABScreen Multi | COVID-19 Diagnostic Solutions and Tools

Avoid TRALI risk by screening for HLA and HNA antibodies

Fast and effective HLA and HNA antibody screening is critical for mitigating the risk of TRALI and improving the safety of convalescent plasma therapy for treating COVID-19. One Lambda’s LABScreen™ Multi solution offers the only FDA-cleared assay for the simultaneous detection of HLA and HNA specific antibodies.


Learn more ❯

LABScreen COVID Plus | COVID-19 Diagnostic Solutions and Tools

Detect COVID-19 Antibodies for a More Complete Antibody Profile

Research has found that pathogen infections similar to COVID-19 can lead to the development of HLA antibodies. With multiple distinct antigens and fragments, the LABScreen™ COVID Plus assay is more specific than current assays and, in combination with HLA antibody detection, can help provide a more complete picture of the patient’s antibody profile.


Learn more ❯

At-home Specimen Collection | COVID-19 Diagnostic Solutions and Tools

Coordinate remote DSA sample collection for your patients

Unfortunately, many transplant patients are avoiding regularly scheduled visits to testing centers during the COVID-19 pandemic. One Lambda has been working on coordinating an at-home specimen collection service to be available to patients who prefer to continue their post-transplant testing plan without traveling to a blood collection site.


Request information ❯

Company Message

At One Lambda, our mission is to help our customers improve the lives of transplant patients and their families. Now, more than ever, we are focused on ensuring that transplant patients are matched and monitored with the very best diagnostic solutions.

In conjunction with Thermo Fisher Scientific, we are monitoring this global situation on a 24-hour basis. We are happy to report that currently there has been no impact to our business and our ability to deliver the One Lambda-branded and Thermo Scientific products that you need to better care for your patients. Furthermore, we are working with our global channel partners to ensure that our customers outside of North America continue to have access to our products and support.

We understand that this is a very fluid situation and events can change in a matter of hours. Please be assured that all our global customers will be notified should there be any impact to our business. View our most recent Covid-19 update ❯

Most importantly, please know that as long as there are patients to be served, we are here to serve you and support you.

Impact of Coronavirus (COVID-19) On Transplant Diagnostics

Here you’ll find the latest news and resources on how COVID-19 may impact the field of transplantation and may transform our understanding of both genotyping and antibody detection.

Would you like to submit a resources that you think may be of interest to the transplant community? Submit Covid-19 Transplant Resource or Comment ❯

Transplant Professionals Resources

Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China

Pub. 4/23/2020

In JAMA Cardiology, this single center study with 362 patients from Wuhan, China, suggests that ACE/ARB may not be a risk factor for #COVID19 in patients with hypertension.

Read free article ❯

Transplant programmes during COVID‐19: Unintended consequences for health inequality

Pub. 4/20/2020

In this letter to the AJT editor, Drs. Shinavi Sharma, Christopher Lawrence (a Thermo Fisher Scientific employee as of March 2020), & Franceso Giovinazzo argue that transplant patients from minority communities or areas of high social deprivation are at risk of the worst health outcomes during the COVID-19 pandemic. Sharma, et al, propose that the transplant community can mitigate the deepening of inequality by working together on creative solutions.

Read free article ❯

Human leukocyte antigen susceptibility map for SARS-CoV-2

Pub. 4/17/2020

Explores how variation in HLA may affect the course of COVID-19 could help identify individuals at higher risk from the disease.

Read free article ❯

COVID-19 in Kidney Transplant Recipients

Pub. 4/09/2020

Direct from the European epicenter of the outbreak, Dr. Iaria Gandolfini, et al, share two cases of successful post-transplant management of COVID-19.

Read free article ❯

Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic

Pub. 4/3/2020

In this paper, Andrew M. South, et al, conclude that there may be concerns about discontinuing usage of ACEi & ARB medications, which are antihypertensive drugs that may cause increased risk of #COVID19 infection. The authors conclude that there are very real concerns about inappropriately stopping these important medications and that more studies are needed to understand the risk involved.

Read free article ❯

Ten Weeks to Crush the Curve

Pub. 4/1/2020

In the New England Journal of Medicine, Harvey Fineberg, MD, PhD, with the Harvard University Department of Health Policy and Management, lays out a comprehensive plan on how we can defeat the pandemic, saving as many lives as possible while minimizing the damage to our economy. A provocative and powerful read for patients and healthcare professionals alike about the high stakes of half measures in this fight against COVID-19.

Read free article ❯

Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma

Pub. 3/27/2020

In this study in Shenzhen, China, patients with COVID-19 and ARDS were treated with convalescent plasma. No mention of testing to mitigate risk of TRALI, but the outcome certainly indicates we need more research on this potential treatment method.

Read free article ❯

Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade.

Pub. 3/13/2020

"...the risk of acquiring COVID-19 from organ donation is low. However, it has been shown that SARS-CoV-2 has a high tropism for the kidney, where it has been shown to replicate in almost 30% of COVID-19 patients. For this reason, screening for COVID-19 in kidney donors should be an important issue. Additionally, living donors who show symptoms or have travelled in high-risk areas should generally be asked to postpone donation for 14–28 days..."

Read free article ❯